Blood test may spot lung cancer recurrence months before scans

NCT ID NCT07257471

Recruiting now Knowledge-focused Sponsor: Beijing Haidian Hospital Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 18, 2026 · Updated 16 times

Summary

This study looks at whether measuring certain DNA markers (SHOX2 and PTGER4) in the blood can detect leftover cancer cells after a minimally invasive procedure called co-ablation for early-stage lung cancer. About 30 people who cannot have surgery will give blood samples before and up to 2 years after treatment. The goal is to see if these markers can predict recurrence earlier than standard imaging, helping doctors tailor follow-up care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Haidian Hospital
RECRUITING

Beijing, Beijing Municipality, 100080, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LUNG CANCER (NSCLC)